X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

Update Sustains OS Benefit of Chemohormonal Therapy in High-Volume Prostate Cancer

Adding docetaxel to androgen-deprivation therapy (ADT) improved overall survival (OS) by nearly 17 months in men with high-volume metastatic hormone-sensitive prostate cancer. Investigators for the multicenter phase III CHAARTED trial noted that the survival benefit did not extend to men with low-volume disease.

Read more.

source: OncLive